^
    Back
    Association details:
    Biomarker:ERBB3 mutation
    Cancer:Urothelial Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

    Excerpt:
    In this phase II trial, patients with metastatic platinum-refractory UC received afatinib 40 mg/day continuously until progression or intolerance...Importantly, molecular alterations of two specific genes—HER2 and ERBB3—were found to be significantly predictive of afatinib efficacy
    DOI:
    10.1200/JCO.2015.66.3047